References
- Mark TL , LevitKR, BuckJA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatric Services60(9) , 1167 (2009).
- Lett TA , WallaceTJ, ChowdhuryNI, TiwariAK, KennedyJL, MüllerDJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry17(3) , 242–266 (2012).
- Maier W , ZobelA. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci.258(1) , 12–20 (2008).
- Hall-Flavin D , WinnerJ, AllenJ et al. Using a pharmacogenetic algorithm to guide the treatment of depression. Transl. Psychiatry 2 , e172 (2012).
- Winner J , AllenJ, AnthonyA, Spahic-MihajlovicA. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl. Psychiatry3 , e242 (2013).
- Neafsey P , GinsbergG, HattisD, SonawaneB. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J. Toxicol. Environ. Health Part B.12 , 334–361 (2009).
- Li-Wan-Po A . Pharmacogenetics and personalized medicine. J. Clin. Pharm. Ther.37 , 617–619 (2012).
- Dickson R , DundarY, FleemanN, JorgensenA, McLeodC, PirmohamedM. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J.1 , 1–14 (2011).
- Shah R , ShahD. Personalized medicine: is it a pharmacogenetic mirage? Br. J. Clin. Pharmacol.74(4) , 698–721 (2012).
- de Leon J , SusceM, PanR, WedlundP, OrregoM, DiazF. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry40(3) , 93–102 (2007).
- Uesawa Y , AbeM, FukudaE, BabaM, OkadaY, MohriK. Construction of a model to estimate the CYP3A inhibitory effect of grapefruit juice. Pharmazie66(7) , 525–528 (2011).
- Seppälä N , LeinonenE, LehtonenM, KivistöK. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol. Toxicol.85(1) , 244–246 (1999).
- Bibi Z . Role of cytochrome P450 in drug interactions. Nutr. Metab.5(27) , 1–10 (2008).
- Chou W , YanF, de Leon J et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol.20(2) , 246–251 (2000).
▪ Website
- Centre for Addiction and Mental Health: Individualized Medicine: Pharmacogenetic Assessment and Clinical Treatment. www.im-pact.ca